HMBD-002 

HMBD-002 is an Fc-independent, non-depleting IgG4 subclass antibody that targets VISTA and VSIG3. It is widely used in research related to various solid tumors, including colon cancer, triple-negative breast cancer, and non-small cell lung cancer. HMBD-002 blocks the interactions of VISTA with VSIG3 and LRIG1, relieves immunosuppression without depleting VISTA-positive cells, activates the cytotoxic program of CD8⁺ T cells, and drives the type I interferon signaling pathway. HMBD-002 reprograms tumor-associated macrophages to the M1 phenotype, reduces tumor infiltration of inhibitory myeloid cells, thereby significantly inhibiting tumor growth and improving survival. HMBD-002 is well tolerated in rodent and non-human primate animal models^[1][2][3][4].

Human IgG4 kappa

Human IgG4 (S228P) kappa, Isotype Control

Human

HMBD-002 (1-10 μg/mL) reverses VSIG3-mediated suppression of activated human PBMCs, with greater activity observed at 10 μg/mL compared to 1 μg/mL in a 1:2 VSIG3-Fc to αCD3 coating ratio assay^[1].
HMBD-002 (1-30 μg/mL) enhances immune activation in human PBMC MLRs, significantly increasing TNF-α and IFN-γ production at a concentration of 30 μg/mL^[1].
HMBD-002 inhibits the interaction between recombinant VISTA and LRIG1 proteins with an IC₅₀ of 3.4 nM^[3].
HMBD-002 (1-10 µg/mL; 24 hours at 37°C) reverses VSIG3-mediated suppression of IFN-γ secretion from anti-CD3-activated human PBMCs, with significant restoration of IFN-γ levels at 1 µg/mL and 10 µg/mL^[3].
HMBD-002 (1-30 µg/mL; 96 hours at 37°C) polarizes the immune milieu toward a proinflammatory Th1/Th17 response in human allogenic MLRs, inducing significant dose-dependent increases in IFN-γ and TNF-α and enriching proinflammatory signaling pathways at 1 µg/mL, 10 µg/mL, and 30 µg/mL^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

HMBD-002 (25 mg/kg; i.p.; biweekly) delivers 84% tumor growth inhibition in a BALB/c mouse CT26 colorectal cancer model, remodels the TME to reduce suppressive myeloid cells and increase activated immune cells, and enhances antigen-specific cytotoxic T cell activity^[3].
HMBD-002 (50 µg; intratumorally; on days 7, 9, 12, 14, 16 post implantation) achieves 53% tumor growth inhibition in a BALB/c mouse orthotopic 4T1 breast cancer model^[3].
HMBD-002 (25 mg/kg; i.p.; biweekly) produces 65% tumor growth inhibition in a humanized HiMouse HCT15 colorectal cancer model^[3].
HMBD-002 (25 mg/kg; i.p.; biweekly) delivers 62% tumor growth inhibition in a humanized HiMouse A549 lung cancer model^[3].
HMBD-002 monotherapy activates the immune system (inducing up to 4-fold increases in serum IL-2, IL-17, and IFNγ) and achieves >60% tumor growth inhibition after 15 days in a CT26 syngeneic colon cancer BALB/C mouse model, with no observable toxicity^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

64115  [NCBI]

Q9H7M9

B7-H5/VISTA

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Dharmadhikari B, et al. The VISTA blocking antibody HMBD-002 promotes type-I interferon signaling and drives anti-tumor responses through macrophage reprograming and cytotoxic CD8+ T cell activation[J]. Memory, 2024, 50: 60.

  [2]. DiMascio L, et al. HMBD-002 is a novel, neutralizing, anti-VISTA antibody exhibiting strong preclinical efficacy and safety, being developed as a monotherapy and in combination with pembrolizumab[J]. 2021.

  [3]. Thakkar D, et al. Rationally targeted anti-VISTA antibody that blockades the C-C’loop region can reverse VISTA immune suppression and remodel the immune microenvironment to potently inhibit tumor growth in an Fc independent manner[J]. Journal for Immunotherapy of Cancer, 2022, 10(2): e003382.

  [4]. Ingram P J, et al. HMBD002, a novel neutralizing antibody targeting a specific epitope on the co-inhibitory immune checkpoint receptor VISTA, displays potent anti-tumor effects in pre-clinical models[J]. Cancer Research, 2017, 77(13_Supplement): 587-587.